PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 5, 2011New England Journal of Medicine7,744 citationsOpen Access

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

View Full Paper
PCPaul B. ChapmanAHAxel HauschildCRCaroline Robert

Key Points

  • The aim is to evaluate the effectiveness of vemurafenib in improving survival rates for melanoma patients with the BRAF V600E mutation.
  • Randomized trial design
  • Evaluated patients with untreated melanoma and BRAF V600E mutation
  • ClinicalTrials.gov number NCT01006980
  • Improved overall survival rates reported in patients treated with vemurafenib, with statistical significance (exact metrics not provided)
  • Progression-free survival rates also improved, indicating beneficial effects of the drug.

Abstract

Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La Roche; BRIM-3 ClinicalTrials.gov number, NCT01006980.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chapman et al. (2011) studied this question.

synapsesocial.com/papers/69d7370bf07a12db70b8a5b5https://doi.org/10.1056/nejmoa1103782
Ask AI
Helpful
Bookmark
Share
View Full Paper